Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016 (2016), Article ID 8917578, 17 pages
http://dx.doi.org/10.1155/2016/8917578
Review Article

Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease

1Department of Medical Sciences, University of Trieste, Cattinara Teaching Hospital, Strada di Fiume, 34100 Trieste, Italy
2Division of Medicina Clinica, Azienda Sanitaria Universitaria Integrata di Trieste (ASUITS), Cattinara Teaching Hospital, Strada di Fiume, 34100 Trieste, Italy
3Diabetes Centre, Azienda Sanitaria Universitaria Integrata di Trieste (ASUITS), Via Puccini, 34100 Trieste, Italy

Received 20 May 2016; Accepted 27 July 2016

Academic Editor: Zhenwu Zhuang

Copyright © 2016 Stella Bernardi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. J. Garcia, P. M. McNamara, T. Gordon, and W. B. Kannell, “Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow up study,” Diabetes, vol. 23, no. 2, pp. 105–111, 1974. View at Publisher · View at Google Scholar · View at Scopus
  2. N. D. F. Russell and M. E. Cooper, “50 years forward: mechanisms of hyperglycaemia-driven diabetic complications,” Diabetologia, vol. 58, no. 8, pp. 1708–1714, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. S. M. Grundy, I. J. Benjamin, G. L. Burke et al., “Diabetes and cardiovascular disease: a statement for healthcare professionals from the american heart association,” Circulation, vol. 100, no. 10, pp. 1134–1146, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. T. K. Schramm, G. H. Gislason, L. Køber et al., “Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people,” Circulation, vol. 117, no. 15, pp. 1945–1954, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais, “Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators,” The New England Journal of Medicine, vol. 342, pp. 145–153, 2000. View at Google Scholar
  6. R. Candido, K. A. Jandeleit-Dahm, Z. Cao et al., “Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice,” Circulation, vol. 106, no. 2, pp. 246–253, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Candido, T. J. Allen, M. Lassila et al., “Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis,” Circulation, vol. 109, no. 12, pp. 1536–1542, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Matsusaka, S. Kinugawa, T. Ide et al., “Angiotensin II type 1 receptor blocker attenuates exacerbated left ventricular remodeling and failure in diabetes-associated myocardial infarction,” Journal of Cardiovascular Pharmacology, vol. 48, no. 3, pp. 95–102, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Fiordaliso, I. Cuccovillo, R. Bianchi et al., “Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes,” Life Sciences, vol. 79, no. 2, pp. 121–129, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Mancia, R. Fagard, K. Narkiewicz et al., “2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC),” European Heart Journal, vol. 34, no. 28, pp. 2159–2219, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Helwig Jr., J. E. Rhoads, and B. Roberts, “The metabolic response to trauma,” Annual Review of Medicine, vol. 7, pp. 141–156, 1956. View at Publisher · View at Google Scholar · View at Scopus
  12. U. G. Friis, B. L. Jensen, J. K. Aas, and O. Skøtt, “Direct demonstration of exocytosis and endocytosis in single mouse juxtaglomerular cells,” Circulation Research, vol. 84, no. 8, pp. 929–936, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. U. G. Friis, B. L. Jensen, S. Sethi, D. Andreasen, P. B. Hansen, and O. Skøtt, “Control of renin secretion from rat juxtaglomerular cells by cAMP-specific phosphodiesterases,” Circulation Research, vol. 90, no. 9, pp. 996–1003, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Braun-Menendez, J. C. Fasciolo, L. F. Leloir, and J. M. Muñoz, “The substance causing renal hypertension,” The Journal of Physiology, vol. 98, no. 3, pp. 283–298, 1940. View at Publisher · View at Google Scholar
  15. E. Braun-Menendez and I. H. Page, “Suggested revision of nomenclature—angiotensin,” Science, vol. 127, no. 3292, p. 242, 1958. View at Google Scholar · View at Scopus
  16. I. H. Page and O. M. Helmer, “A crystalline pressor substance (Angiotonin) resulting from the reaction between renin and renin-activator,” Journal of Experimental Medicine, vol. 71, no. 1, pp. 29–42, 1940. View at Publisher · View at Google Scholar
  17. S. Whitebread, M. Mele, B. Kamber, and M. de Gasparo, “Preliminary biochemical characterization of two angiotensin II receptor subtypes,” Biochemical and Biophysical Research Communications, vol. 163, no. 1, pp. 284–291, 1989. View at Publisher · View at Google Scholar · View at Scopus
  18. M. de Gasparo, K. J. Catt, T. Inagami, J. W. Wright, and T. Unger, “International union of pharmacology. XXIII. The angiotensin II receptors,” Pharmacological Reviews, vol. 52, no. 3, pp. 415–472, 2000. View at Google Scholar · View at Scopus
  19. G. H. Williams, “Aldosterone biosynthesis, regulation, and classical mechanism of action,” Heart Failure Reviews, vol. 10, no. 1, pp. 7–13, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Ito, M. I. Oliverio, P. J. Mannon et al., “Regulation of blood pressure by the type 1A angiotensin II receptor gene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 8, pp. 3521–3525, 1995. View at Publisher · View at Google Scholar · View at Scopus
  21. M. I. liverio, H.-S. Kim, M. Ito et al., “Reduced growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 26, pp. 15496–15501, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. M. I. Oliverio, K. Madsen, C. F. Best et al., “Renal growth and development in mice lacking AT(1A) receptors for angiotensin II,” American Journal of Physiology-Renal Physiology, vol. 274, no. 1, pp. F43–F50, 1998. View at Google Scholar · View at Scopus
  23. S. Shanmugam, P. Corvol, and J.-M. Gasc, “Angiotensin II type 2 receptor mRNA expression in the developing cardiopulmonary system of the rat,” Hypertension, vol. 28, no. 1, pp. 91–97, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. E. S. Jones, A. Vinh, C. A. McCarthy, T. A. Gaspari, and R. E. Widdop, “AT2 receptors: functional relevance in cardiovascular disease,” Pharmacology and Therapeutics, vol. 120, no. 3, pp. 292–316, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Hein, G. S. Barsh, R. E. Pratt, V. J. Dzau, and B. K. Kobilka, “Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice,” Nature, vol. 377, no. 6551, pp. 744–747, 1995. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Ichiki, P. A. Labosky, C. Shiota et al., “Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor,” Nature, vol. 377, no. 6551, pp. 748–750, 1995. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Tsutsumi, H. Matsubara, H. Masaki et al., “Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation,” Journal of Clinical Investigation, vol. 104, no. 7, pp. 925–935, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. H. M. Siragy, T. Inagami, T. Ichiki, and R. M. Carey, “Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 11, pp. 6506–6510, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Tanaka, S. Tsuchida, T. Imai et al., “Vascular response to angiotensin II is exaggerated through an upregulation of AT1 receptor in AT2 knockout mice,” Biochemical and Biophysical Research Communications, vol. 258, no. 1, pp. 194–198, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Bedecs, N. Elbaz, M. Sutren et al., “Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase,” Biochemical Journal, vol. 325, no. 2, pp. 449–454, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. S. AbdAlla, H. Lother, A. M. Abdel-tawab, and U. Quitterer, “The angiotensin II AT2 receptor is an AT1 receptor antagonist,” Journal of Biological Chemistry, vol. 276, no. 43, pp. 39721–39726, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Seravalle, B. M. Cattaneo, C. Giannattasio et al., “RAA system and cardiovascular control in normal subjects, hypertensives and patients with congestive heart failure,” Journal of Human Hypertension, vol. 7, no. 2, pp. S13–S18, 1993. View at Google Scholar · View at Scopus
  33. M. A. Ondetti, B. Rubin, and D. W. Cushman, “Design of specific inhibitors of angiotensin converting enzyme: new class of orally active antihypertensive agents,” Science, vol. 196, no. 4288, pp. 441–444, 1977. View at Publisher · View at Google Scholar · View at Scopus
  34. P. B. M. W. M. Timmermans, J. V. Duncia, D. J. Carini et al., “Discovery of losartan, the first angiotensin II receptor antagonist,” Journal of Human Hypertension, vol. 9, supplement 5, pp. S3–S18, 1995. View at Google Scholar · View at Scopus
  35. The CONSENSUS Trial Study Group, “Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS),” The New England Journal of Medicine, vol. 316, no. 23, pp. 1429–1435, 1987. View at Google Scholar
  36. The SOLVD Investigators, “Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure,” The New England Journal of Medicine, vol. 325, no. 5, pp. 293–302, 1991. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Ikeda, T. Nakamura, H. Takano et al., “Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats,” Journal of Laboratory and Clinical Medicine, vol. 135, no. 4, pp. 353–359, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Yamazaki and Y. Yazaki, “Role of tissue angiotensin II in myocardial remodelling induced by mechanical stress,” Journal of Human Hypertension, vol. 13, supplement 1, pp. S43–S50, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Mazzolai, T. Pedrazzini, F. Nicoud, G. Gabbiani, H.-R. Brunner, and J. Nussberger, “Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice,” Hypertension, vol. 35, no. 4, pp. 985–991, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Gavras, A. F. Lever, J. J. Brown, R. F. Macadam, and J. I. S. Robertson, “Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II,” The Lancet, vol. 298, no. 7714, pp. 19–22, 1971. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Daugherty and L. Cassis, “Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice,” Annals of the New York Academy of Sciences, vol. 892, pp. 108–118, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Daugherty, M. W. Manning, and L. A. Cassis, “Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice,” Journal of Clinical Investigation, vol. 105, no. 11, pp. 1605–1612, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. D. Weiss, J. J. Kools, and W. R. Taylor, “Angiotensin II-induced hypertension accelerates the development of atherosclerosis in ApoE-deficient mice,” Circulation, vol. 103, no. 3, pp. 448–454, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. J.-I. Sadoshima and S. Izumo, “Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts critical role of the AT1 receptor subtype,” Circulation Research, vol. 73, no. 3, pp. 413–423, 1993. View at Publisher · View at Google Scholar · View at Scopus
  45. F. J. Villarreal, N. N. Kim, G. D. Ungab, M. P. Printz, and W. H. Dillmann, “Identification of functional angiotensin II receptors on rat cardiac fibroblasts,” Circulation, vol. 88, no. 6, pp. 2849–2861, 1993. View at Publisher · View at Google Scholar · View at Scopus
  46. D. C. Crawford, A. V. Chobanian, and P. Brecher, “Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat,” Circulation Research, vol. 74, no. 4, pp. 727–739, 1994. View at Publisher · View at Google Scholar · View at Scopus
  47. R. S. Ostrom, J. E. Naugle, M. Hase et al., “Angiotensin II enhances adenylyl cyclase signaling via Ca2+/calmodulin. Gq-Gs cross-talk regulates collagen production in cardiac fibroblasts,” The Journal of Biological Chemistry, vol. 278, pp. 24461–24468, 2003. View at Publisher · View at Google Scholar
  48. G. Zhou, J. C. Kandala, S. C. Tyagi, L. C. Katwa, and K. T. Weber, “Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts,” Molecular and Cellular Biochemistry, vol. 154, no. 2, pp. 171–178, 1996. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Zhang, A. Schmeißer, C. D. Garlichs et al., “Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases,” Cardiovascular Research, vol. 44, no. 1, pp. 215–222, 1999. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Pastore, A. Tessitore, S. Martinotti et al., “Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo,” Circulation, vol. 100, no. 15, pp. 1646–1652, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. M. C. Thomas, R. J. Pickering, D. Tsorotes et al., “Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse,” Circulation Research, vol. 107, no. 7, pp. 888–897, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Rajagopalan, S. Kurz, T. Münzel et al., “Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone,” Journal of Clinical Investigation, vol. 97, no. 8, pp. 1916–1923, 1996. View at Publisher · View at Google Scholar · View at Scopus
  53. A. A. Geisterfer, M. J. Peach, and G. K. Owens, “Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells,” Circulation Research, vol. 62, no. 4, pp. 749–756, 1988. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Itoh, M. Mukoyama, R. E. Pratt, G. H. Gibbons, and V. J. Dzau, “Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II,” Journal of Clinical Investigation, vol. 91, no. 5, pp. 2268–2274, 1993. View at Publisher · View at Google Scholar · View at Scopus
  55. M. J. A. P. Daemen, D. M. Lombardi, F. T. Bosman, and S. M. Schwartz, “Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall,” Circulation Research, vol. 68, no. 2, pp. 450–456, 1991. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Bell and J. A. Madri, “Influence of the angiotensin system on endothelial and smooth muscle cell migration,” American Journal of Pathology, vol. 137, no. 1, pp. 7–12, 1990. View at Google Scholar · View at Scopus
  57. R. K. Dubey, E. K. Jackson, and T. F. Lüscher, “Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors,” The Journal of Clinical Investigation, vol. 96, no. 1, pp. 141–149, 1995. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Scott-Burden, A. W. A. Hahn, T. J. Resink, and F. R. Buhler, “Modulation of extracellular matrix by angiotensin II: stimulated glycoconjugate synthesis and growth in vascular smooth muscle cells,” Journal of Cardiovascular Pharmacology, vol. 16, supplement 4, pp. S36–S41, 1990. View at Google Scholar · View at Scopus
  59. A. W. A. Hahn, U. Jonas, F. R. Bühler, and T. J. Resink, “Activation of human peripheral monocytes by angiotensin II,” FEBS Letters, vol. 347, no. 2-3, pp. 178–180, 1994. View at Publisher · View at Google Scholar · View at Scopus
  60. P. Lijnen and V. Petrov, “Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes,” Journal of Molecular and Cellular Cardiology, vol. 31, no. 5, pp. 949–970, 1999. View at Publisher · View at Google Scholar · View at Scopus
  61. J. M. Schnee and W. A. Hsueh, “Angiotensin II, adhesion, and cardiac fibrosis,” Cardiovascular Research, vol. 46, no. 2, pp. 264–268, 2000. View at Publisher · View at Google Scholar · View at Scopus
  62. B. Fabris, R. Candido, M. Bortoletto et al., “Dose and time-dependent apoptotic effects by angiotensin II infusion on left ventricular cardiomyocytes,” Journal of Hypertension, vol. 25, no. 7, pp. 1481–1490, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. B. Fabris, R. Candido, M. Bortoletto et al., “Stimulation of cardiac apoptosis in ovariectomized hypertensive rats: potential role of the renin-angiotensin system,” Journal of Hypertension, vol. 29, no. 2, pp. 273–281, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. D. J. Campbell, “Circulating and tissue angiotensin systems,” Journal of Clinical Investigation, vol. 79, no. 1, pp. 1–6, 1987. View at Publisher · View at Google Scholar · View at Scopus
  65. V. J. Dzau, “Circulating versus local renin-angiotensin system in cardiovascular homeostasis,” Circulation, vol. 77, no. 6, pp. 4–13, 1988. View at Google Scholar · View at Scopus
  66. C. I. Johnston, “Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control,” Journal of Hypertension, vol. 10, pp. S13–S26, 1992. View at Google Scholar · View at Scopus
  67. V. J. Dzau and R. Re, “Tissue angiotensin system in cardiovascular medicine: a paradigm shift?” Circulation, vol. 89, no. 1, pp. 493–498, 1994. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Paul, J. Wagner, and V. J. Dzau, “Gene expression of the renin-angiotensin system in human tissues: quantitative analysis by the polymerase chain reaction,” Journal of Clinical Investigation, vol. 91, no. 5, pp. 2058–2064, 1993. View at Publisher · View at Google Scholar · View at Scopus
  69. F. A. O. Mendelsohn, “Localization and properties of angiotensin receptors,” Journal of Hypertension, vol. 3, no. 4, pp. 307–316, 1985. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Inagami, N. Iwai 1, K. Sasaki 1 et al., “Cloning, expression and regulation of angiotensin II receptors,” Journal of Hypertension, vol. 10, no. 8, pp. 713–716, 1992. View at Google Scholar · View at Scopus
  71. C. I. Johnston, “Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling,” Hypertension, vol. 23, no. 2, pp. 258–268, 1994. View at Publisher · View at Google Scholar · View at Scopus
  72. R. Kumar, Q. C. Yong, C. M. Thomas, and K. M. Baker, “Intracardiac intracellular angiotensin system in diabetes,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 302, no. 5, pp. R510–R517, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Bernardi, B. Toffoli, C. Zennaro et al., “High-salt diet increases glomerular ACE/ACE2 ratio leading to oxidative stress and kidney damage,” Nephrology, Dialysis, Transplantation, vol. 27, no. 5, pp. 1793–1800, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Schunkert, V. J. Dzau, S. S. Tang, A. T. Hirsch, C. S. Apstein, and B. H. Lorell, “Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy: effects on coronary resistance, contractility, and relaxation,” Journal of Clinical Investigation, vol. 86, no. 6, pp. 1913–1920, 1990. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Hokimoto, H. Yasue, K. Fujimoto et al., “Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction,” Circulation, vol. 94, no. 7, pp. 1513–1518, 1996. View at Publisher · View at Google Scholar · View at Scopus
  76. A. T. Hirsch, C. E. Talsness, H. Schunkert, M. Paul, and V. J. Dzau, “Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure,” Circulation Research, vol. 69, no. 2, pp. 475–482, 1991. View at Publisher · View at Google Scholar · View at Scopus
  77. F. Pieruzzi, Z. A. Abassi, and H. R. Keiser, “Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure,” Circulation, vol. 92, no. 10, pp. 3105–3112, 1995. View at Publisher · View at Google Scholar · View at Scopus
  78. K. C. Wollert and H. Drexler, “The renin-angiotensin system and experimental heart failure,” Cardiovascular Research, vol. 43, no. 4, pp. 838–849, 1999. View at Publisher · View at Google Scholar · View at Scopus
  79. A. T. Hirsch, Y. M. Pinto, H. Schunkert, and V. J. Dzau, “Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure,” The American Journal of Cardiology, vol. 66, no. 11, pp. D22–D32, 1990. View at Publisher · View at Google Scholar · View at Scopus
  80. L. H. Lindholm, H. Ibsen, B. Dahlöf et al., “Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol,” The Lancet, vol. 359, no. 9311, pp. 1004–1010, 2002. View at Publisher · View at Google Scholar · View at Scopus
  81. C. A. Daly, K. M. Fox, W. J. Remme, M. E. Bertrand, R. Ferrari, and M. L. Simoons, “The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy,” European Heart Journal, vol. 26, no. 14, pp. 1369–1378, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Patel, A. C. Group, S. MacMahon et al., “Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial,” The Lancet, vol. 370, pp. 829–840, 2007. View at Google Scholar
  83. S. Yusuf, K. K. Teo, J. Pogue et al., “Telmisartan, ramipril, or both in patients at high risk for vascular events,” The New England Journal of Medicine, vol. 358, pp. 1547–1559, 2008. View at Publisher · View at Google Scholar
  84. B. Pitt, F. Zannad, W. J. Remme et al., “The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators,” The New England Journal of Medicine, vol. 341, no. 10, pp. 709–717, 1999. View at Publisher · View at Google Scholar · View at Scopus
  85. B. Pitt, W. Remme, F. Zannad et al., “Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction,” The New England Journal of Medicine, vol. 348, no. 14, pp. 1309–1321, 2003. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Yamamuro, M. Yoshimura, M. Nakayama et al., “Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium,” Endocrinology, vol. 147, no. 3, pp. 1314–1321, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. H. Hayashi, M. Kobara, M. Abe et al., “Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis,” Hypertension Research, vol. 31, no. 2, pp. 363–375, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. J. D. Stockand and J. G. Meszaros, “Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 284, no. 1, pp. H176–H184, 2003. View at Publisher · View at Google Scholar · View at Scopus
  89. C. G. Brilla, G. Zhou, L. Matsubara, and K. T. Weber, “Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone,” Journal of Molecular and Cellular Cardiology, vol. 26, no. 7, pp. 809–820, 1994. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Bunda, Y. Wang, T. F. Mitts et al., “Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of Gα13, c-Src, the insulin-like growth factor-I receptor, and phosphatidylinositol 3-kinase/Akt,” Journal of Biological Chemistry, vol. 284, no. 24, pp. 16633–16647, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. J. A. Leopold, A. Dam, B. A. Maron et al., “Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity,” Nature Medicine, vol. 13, no. 2, pp. 189–197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Caprio, B. G. Newfell, A. La Sala et al., “Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion,” Circulation Research, vol. 102, no. 11, pp. 1359–1367, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. L.-J. Min, M. Mogi, J.-M. Li, J. Iwanami, M. Iwai, and M. Horiuchi, “Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells,” Circulation Research, vol. 97, no. 5, pp. 434–442, 2005. View at Publisher · View at Google Scholar · View at Scopus
  94. A. C. Montezano, G. E. Callera, A. Yogi et al., “Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated Redox-sensitive RhoA pathways,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 8, pp. 1511–1518, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. D. Pruthi, A. Mccurley, M. Aronovitz, C. Galayda, S. A. Karumanchi, and I. Z. Jaffe, “Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 2, pp. 355–364, 2014. View at Publisher · View at Google Scholar · View at Scopus
  96. C. Grossmann, A. W. Krug, R. Freudinger, S. Mildenberger, K. Voelker, and M. Gekle, “Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter,” American Journal of Physiology—Endocrinology and Metabolism, vol. 292, no. 6, pp. E1790–E1800, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. M. G. Usher, S. Z. Duan, C. Y. Ivaschenko et al., “Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice,” Journal of Clinical Investigation, vol. 120, no. 9, pp. 3350–3364, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Keidar, M. Kaplan, E. Pavlotzky et al., “Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin ii and aldosterone,” Circulation, vol. 109, no. 18, pp. 2213–2220, 2004. View at Publisher · View at Google Scholar · View at Scopus
  99. W. Qin, A. E. Rudolph, B. R. Bond et al., “Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure,” Circulation Research, vol. 93, no. 1, pp. 69–76, 2003. View at Publisher · View at Google Scholar · View at Scopus
  100. M. Young, M. Fullerton, R. Dilley, and J. Funder, “Mineralocorticoids, hypertension, and cardiac fibrosis,” The Journal of Clinical Investigation, vol. 93, no. 6, pp. 2578–2583, 1994. View at Publisher · View at Google Scholar · View at Scopus
  101. J.-C. Reil, M. Hohl, S. Selejan et al., “Aldosterone promotes atrial fibrillation,” European Heart Journal, vol. 33, no. 16, pp. 2098–2108, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. Y. Sun, J. Zhang, L. Lu, S. S. Chen, M. T. Quinn, and K. T. Weber, “Aldosterone-induced inflammation in the rat heart: role of oxidative stress,” American Journal of Pathology, vol. 161, no. 5, pp. 1773–1781, 2002. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Rajagopalan, D. Duquaine, S. King, B. Pitt, and P. Patel, “Mineralocorticoid receptor antagonism in experimental atherosclerosis,” Circulation, vol. 105, no. 18, pp. 2212–2216, 2002. View at Publisher · View at Google Scholar · View at Scopus
  104. J. H. O'Keefe, H. Abuissa, and B. Pitt, “Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS,” Diabetes, Obesity and Metabolism, vol. 10, no. 6, pp. 492–497, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. B. Pitt, S. D. Anker, M. Böhm et al., “Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease,” European Journal of Heart Failure, vol. 17, no. 2, pp. 224–232, 2015. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Donoghue, F. Hsieh, E. Baronas et al., “A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9,” Circulation Research, vol. 87, no. 5, pp. E1–E9, 2000. View at Google Scholar · View at Scopus
  107. S. R. Tipnis, N. M. Hooper, R. Hyde, E. Karran, G. Christie, and A. J. Turner, “A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase,” The Journal of Biological Chemistry, vol. 275, no. 43, pp. 33238–33243, 2000. View at Publisher · View at Google Scholar · View at Scopus
  108. C. Vickers, P. Hales, V. Kaushik et al., “Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase,” The Journal of Biological Chemistry, vol. 277, no. 17, pp. 14838–14843, 2002. View at Publisher · View at Google Scholar · View at Scopus
  109. G. I. Rice, D. A. Thomas, P. J. Grant, A. J. Turner, and N. M. Hooper, “Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism,” Biochemical Journal, vol. 383, no. 1, pp. 45–51, 2004. View at Publisher · View at Google Scholar · View at Scopus
  110. C. M. Ferrario, M. C. Chappell, E. A. Tallant, K. B. Brosnihan, and D. I. Diz, “Counterregulatory actions of angiotensin-(1–7),” Hypertension, vol. 30, no. 3, pp. 535–541, 1997. View at Publisher · View at Google Scholar · View at Scopus
  111. R. A. S. Santos, A. C. Simoes e Silva, C. Maric et al., “Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8258–8263, 2003. View at Publisher · View at Google Scholar · View at Scopus
  112. E. A. Tallant, C. M. Ferrario, and P. E. Gallagher, “Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 289, no. 4, pp. H1560–H1566, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Flores-Muñoz, B. M. D. C. Godinho, A. Almalik, and S. A. Nicklin, “Adenoviral delivery of angiotensin-(1–7) or angiotensin-(1–9) inhibits cardiomyocyte hypertrophy via the mas or angiotensin type 2 receptor,” PLoS ONE, vol. 7, no. 9, article e45564, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. X. Niu, Y. Xue, X. Li et al., “Effects of angiotensin-(1-7) on the proliferation and collagen synthesis of arginine vasopressin–stimulated rat cardiac fibroblasts: role of mas receptor-calcineurin-NF-κB signaling pathway,” Journal of Cardiovascular Pharmacology, vol. 64, no. 6, pp. 536–542, 2014. View at Publisher · View at Google Scholar · View at Scopus
  115. L. T. McCollum, P. E. Gallagher, and E. A. Tallant, “Angiotensin-(1–7) abrogates mitogen-stimulated proliferation of cardiac fibroblasts,” Peptides, vol. 34, no. 2, pp. 380–388, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. W. O. Sampaio, R. A. S. Dos Santos, R. Faria-Silva, L. T. Da Mata Machado, E. L. Schiffrin, and R. M. Touyz, “Angiotensin-(1–7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways,” Hypertension, vol. 49, no. 1, pp. 185–192, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. Y.-H. Zhang, Y.-H. Zhang, X.-F. Dong et al., “ACE2 and Ang-(1–7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response,” Inflammation Research, vol. 64, no. 3-4, pp. 253–260, 2015. View at Publisher · View at Google Scholar · View at Scopus
  118. E. J. Freeman, G. M. Chisolm, C. M. Ferrario, and E. A. Tallant, “Angiotensin-(1–7) inhibits vascular smooth muscle cell growth,” Hypertension, vol. 28, no. 1, pp. 104–108, 1996. View at Publisher · View at Google Scholar · View at Scopus
  119. E. A. Tallant, D. I. Diz, and C. M. Ferrario, “Antiproliferative actions of angiotensin-(1–7) in vascular smooth muscle,” Hypertension, vol. 34, no. 4, pp. 950–957, 1999. View at Publisher · View at Google Scholar · View at Scopus
  120. L. L. Souza and C. M. Costa-Neto, “Angiotensin-(1–7) decreases LPS-induced inflammatory response in macrophages,” Journal of Cellular Physiology, vol. 227, no. 5, pp. 2117–2122, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. A. J. Ferreira, R. A. Santos, and A. P. Almeida, “Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion,” Hypertension, vol. 38, no. 3, pp. 665–668, 2001. View at Publisher · View at Google Scholar · View at Scopus
  122. J. L. Grobe, A. P. Mecca, H. Mao, and M. J. Katovich, “Chronic angiotensin-(1–7) prevents cardiac fibrosis in DOCA-salt model of hypertension,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 290, no. 6, pp. H2417–H2423, 2006. View at Publisher · View at Google Scholar · View at Scopus
  123. A. J. Ferreira, T. L. Oliveira, M. C. M. Castro et al., “Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1–7) analogue AVE 0991,” Life Sciences, vol. 81, no. 11, pp. 916–923, 2007. View at Publisher · View at Google Scholar · View at Scopus
  124. N. M. Santiago, P. S. Guimarães, R. A. Sirvente et al., “Lifetime overproduction of circulating angiotensin-(1–7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling,” Hypertension, vol. 55, no. 4, pp. 889–896, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. E. R. M. Gomes, A. A. Lara, P. W. M. Almeida et al., “Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3′,5′-cyclic monophosphate-dependent pathway,” Hypertension, vol. 55, no. 1, pp. 153–160, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. R. A. S. Santos, C. H. Castro, E. Gava et al., “Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor mas knockout mice,” Hypertension, vol. 47, no. 5, pp. 996–1002, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. K. B. Brosnihan, P. Li, and C. M. Ferrario, “Angiotensin-(1–7) dilates canine coronary arteries through kinins and nitric oxide,” Hypertension, vol. 27, no. 3, pp. 523–528, 1996. View at Publisher · View at Google Scholar · View at Scopus
  128. S. Tesanovic, A. Vinh, T. A. Gaspari, D. Casley, and R. E. Widdop, “Vasoprotective and atheroprotective effects of angiotensin (1–7) in apolipoprotein E-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 8, pp. 1606–1613, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. S. Bosnyak, E. S. Jones, A. Christopoulos, M.-I. Aguilar, W. G. Thomas, and R. E. Widdop, “Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors,” Clinical Science, vol. 121, no. 7, pp. 297–303, 2011. View at Publisher · View at Google Scholar · View at Scopus
  130. M. K. Raizada and A. J. Ferreira, “ACE2: a new target for cardiovascular disease therapeutics,” Journal of Cardiovascular Pharmacology, vol. 50, no. 2, pp. 112–119, 2007. View at Publisher · View at Google Scholar · View at Scopus
  131. V. B. Patel, J. C. Zhong, M. B. Grant, and G. Y. Oudit, “Role of the ACE2/angiotensin 1–7 axis of the renin-angiotensin system in heart failure,” Circulation Research, vol. 118, no. 8, pp. 1313–1326, 2016. View at Publisher · View at Google Scholar
  132. S. Bernardi, W. C. Burns, B. Toffoli et al., “Angiotensin-converting enzyme 2 regulates renal atrial natriuretic peptide through angiotensin-(1–7),” Clinical Science, vol. 123, no. 1, pp. 29–37, 2012. View at Publisher · View at Google Scholar · View at Scopus
  133. G. Nguyen, F. Delarue, C. Burcklé, L. Bouzhir, T. Giller, and J.-D. Sraer, “Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin,” The Journal of Clinical Investigation, vol. 109, no. 11, pp. 1417–1427, 2002. View at Publisher · View at Google Scholar · View at Scopus
  134. G. Nguyen and D. N. Muller, “The biology of the (pro)renin receptor,” Journal of the American Society of Nephrology, vol. 21, no. 1, pp. 18–23, 2010. View at Publisher · View at Google Scholar · View at Scopus
  135. T. Hirose, M. Hashimoto, K. Totsune et al., “Association of (pro)renin receptor gene polymorphism with blood pressure in Japanese men: the Ohasama study,” American Journal of Hypertension, vol. 22, no. 3, pp. 294–299, 2009. View at Publisher · View at Google Scholar · View at Scopus
  136. J. J. Saris, P. A. C. 't Hoen, I. M. Garrelds et al., “Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II,” Hypertension, vol. 48, no. 4, pp. 564–571, 2006. View at Publisher · View at Google Scholar · View at Scopus
  137. M. Véniant, J. Ménard, P. Bruneval, S. Morley, M. F. Gonzales, and J. Mullins, “Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver,” The Journal of Clinical Investigation, vol. 98, no. 9, pp. 1966–1970, 1996. View at Publisher · View at Google Scholar · View at Scopus
  138. J. J. Saris, M. M. E. D. van den Eijnden, J. M. J. Lamers, P. R. Saxena, M. A. D. H. Schalekamp, and A. H. J. Danser, “Prorenin-induced myocyte proliferation: no role for intracellular angiotensin II,” Hypertension, vol. 39, no. 2, pp. 573–577, 2002. View at Publisher · View at Google Scholar · View at Scopus
  139. S. Hinrichs, J. Heger, R. Schreckenberg et al., “Controlling cardiomyocyte length: the role of renin and PPAR-γ,” Cardiovascular Research, vol. 89, no. 2, pp. 344–352, 2011. View at Publisher · View at Google Scholar · View at Scopus
  140. M. Uraoka, K. Ikeda, Y. Nakagawa et al., “Prorenin induces ERK activation in endothelial cells to enhance neovascularization independently of the renin-angiotensin system,” Biochemical and Biophysical Research Communications, vol. 390, no. 4, pp. 1202–1207, 2009. View at Publisher · View at Google Scholar · View at Scopus
  141. M. Sakoda, A. Ichihara, Y. Kaneshiro et al., “(Pro)renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells,” Hypertension Research, vol. 30, no. 11, pp. 1139–1146, 2007. View at Publisher · View at Google Scholar · View at Scopus
  142. F. Y. Liu, X. Y. Liu, L. J. Zhang, Y. P. Cheng, and Y. N. Jiang, “Binding of prorenin to (pro)renin receptor induces the proliferation of human umbilical artery smooth muscle cells via ROS generation and ERK1/2 activation,” JRAAS-Journal of the Renin-Angiotensin-Aldosterone System, vol. 15, no. 2, pp. 99–108, 2014. View at Publisher · View at Google Scholar · View at Scopus
  143. K. Narumi, T. Hirose, E. Sato et al., “A functional (pro)renin receptor is expressed in human lymphocytes and monocytes,” American Journal of Physiology—Renal Physiology, vol. 308, no. 5, pp. F487–F499, 2015. View at Publisher · View at Google Scholar · View at Scopus
  144. A.-M. Moilanen, J. Rysä, R. Serpi et al., “(Pro)renin receptor triggers distinct angiotensin ii-independent extracellular matrix remodeling and deterioration of cardiac function,” PLoS ONE, vol. 7, no. 7, article e41404, 2012. View at Publisher · View at Google Scholar · View at Scopus
  145. A. Kanda, K. Noda, W. Saito, and S. Ishida, “(Pro)renin receptor is associated with angiogenic activity in proliferative diabetic retinopathy,” Diabetologia, vol. 55, no. 11, pp. 3104–3113, 2012. View at Publisher · View at Google Scholar · View at Scopus
  146. B. Peters, O. Grisk, B. Becher et al., “Dose-dependent titration of prorenin and blood pressure in Cyp1a1ren-2 transgenic rats: absence of prorenin-induced glomerulosclerosis,” Journal of Hypertension, vol. 26, no. 1, pp. 102–109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  147. C. Mercure, G. Prescott, M.-J. Lacombe, D. W. Silversides, and T. L. Reudelhuber, “Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies,” Hypertension, vol. 53, no. 6, pp. 1062–1069, 2009. View at Publisher · View at Google Scholar · View at Scopus
  148. W. W. Batenburg and A. H. Jan Danser, “(Pro)renin and its receptors: pathophysiological implications,” Clinical Science, vol. 123, no. 3, pp. 121–133, 2012. View at Publisher · View at Google Scholar · View at Scopus
  149. T. Nishi and M. Forgac, “The vacuolar (H+)-ATPases—nature's most versatile proton pumps,” Nature Reviews Molecular Cell Biology, vol. 3, no. 2, pp. 94–103, 2002. View at Publisher · View at Google Scholar · View at Scopus
  150. A. Advani, D. J. Kelly, A. J. Cox et al., “The (Pro)renin receptor: site-specific and functional linkage to the vacuolar H+-atpase in the kidney,” Hypertension, vol. 54, no. 2, pp. 261–269, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. J. Ramser, F. E. Abidi, C. A. Burckle et al., “A unique exonic splice enhancer mutation in a family with X-linked mental retardation and epilepsy points to a novel role of the renin receptor,” Human Molecular Genetics, vol. 14, no. 8, pp. 1019–1027, 2005. View at Publisher · View at Google Scholar · View at Scopus
  152. A. Contrepas, J. Walker, A. Koulakoff et al., “A role of the (pro)renin receptor in neuronal cell differentiation,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 297, no. 2, pp. R250–R257, 2009. View at Publisher · View at Google Scholar · View at Scopus
  153. C.-M. Cruciat, B. Ohkawara, S. P. Acebron et al., “Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling,” Science, vol. 327, no. 5964, pp. 459–463, 2010. View at Publisher · View at Google Scholar · View at Scopus
  154. A. Amsterdam, R. M. Nissen, Z. Sun, E. C. Swindell, S. Farrington, and N. Hopkins, “Identification of 315 genes essential for early zebrafish development,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 35, pp. 12792–12797, 2004. View at Publisher · View at Google Scholar · View at Scopus
  155. K. Kinouchi, A. Ichihara, M. Sano et al., “The (pro)renin receptor/ATP6AP2 is essential for vacuolar H+-ATPase assembly in murine cardiomyocytes,” Circulation Research, vol. 107, no. 1, pp. 30–34, 2010. View at Publisher · View at Google Scholar · View at Scopus
  156. S. Rubler, J. Dlugash, Y. Z. Yuceoglu, T. Kumral, A. W. Branwood, and A. Grishman, “New type of cardiomyopathy associated with diabetic glomerulosclerosis,” The American Journal of Cardiology, vol. 30, no. 6, pp. 595–602, 1972. View at Publisher · View at Google Scholar · View at Scopus
  157. J. A. Miller, J. S. Floras, B. Zinman, K. L. Skorecki, and A. G. Logan, “Effect of hyperglycaemia on arterial pressure, plasma renin activity and renal function in early diabetes,” Clinical Science, vol. 90, no. 3, pp. 189–195, 1996. View at Publisher · View at Google Scholar · View at Scopus
  158. J. A. Miller, “Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus,” Journal of the American Society of Nephrology, vol. 10, no. 8, pp. 1778–1785, 1999. View at Google Scholar · View at Scopus
  159. S. Y. Osei, D. A. Price, L. M. B. Laffel, M. C. Lansang, and N. K. Hollenberg, “Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans,” Hypertension, vol. 36, no. 1, pp. 122–126, 2000. View at Publisher · View at Google Scholar · View at Scopus
  160. S. D. Solomon, E. Appelbaum, W. J. Manning et al., “Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy,” Circulation, vol. 119, no. 4, pp. 530–537, 2009. View at Publisher · View at Google Scholar · View at Scopus
  161. A. M. Shah, S. H. Shin, M. Takeuchi et al., “Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren,” European Journal of Heart Failure, vol. 14, no. 2, pp. 185–192, 2012. View at Publisher · View at Google Scholar · View at Scopus
  162. F. Fiordaliso, B. Li, R. Latini et al., “Myocyte death in streptozotocin-induced diabetes in rats is angiotensin II- dependent,” Laboratory Investigation, vol. 80, no. 4, pp. 513–527, 2000. View at Publisher · View at Google Scholar · View at Scopus
  163. V. P. Singh, B. Le, V. B. Bhat, K. M. Baker, and R. Kumar, “High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 293, no. 2, pp. H939–H948, 2007. View at Publisher · View at Google Scholar · View at Scopus
  164. V. P. Singh, K. M. Baker, and R. Kumar, “Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 294, no. 4, pp. H1675–H1684, 2008. View at Publisher · View at Google Scholar · View at Scopus
  165. R. Tang, Q. Li, L. Lv et al., “Angiotensin II mediates the high-glucose-induced endothelial-to-mesenchymal transition in human aortic endothelial cells,” Cardiovascular Diabetology, vol. 9, article no. 31, 2010. View at Publisher · View at Google Scholar · View at Scopus
  166. A. Frustaci, J. Kajstura, C. Chimenti et al., “Myocardial cell death in human diabetes,” Circulation Research, vol. 87, no. 12, pp. 1123–1132, 2000. View at Publisher · View at Google Scholar · View at Scopus
  167. F. Fiordaliso, A. Leri, D. Cesselli et al., “Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death,” Diabetes, vol. 50, no. 10, pp. 2363–2375, 2001. View at Publisher · View at Google Scholar · View at Scopus
  168. V. P. Singh, B. Le, R. Khode, K. M. Baker, and R. Kumar, “Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis,” Diabetes, vol. 57, pp. 3297–3306, 2008. View at Google Scholar
  169. R. Natarajan, S. Scott, B. Wei, K. K. V. Yerneni, and J. Nadler, “Angiotensin II signaling in vascular smooth muscle cells under high glucose conditions,” Hypertension, vol. 33, no. 1, pp. 378–384, 1999. View at Publisher · View at Google Scholar · View at Scopus
  170. K. H. S. Arun, C. L. Kaul, and P. Ramarao, “High glucose concentration augments angiotensin II mediated contraction via AT1 receptors in rat thoracic aorta,” Pharmacological Research, vol. 50, no. 6, pp. 561–568, 2004. View at Publisher · View at Google Scholar · View at Scopus
  171. L. A. Sechi, C. A. Griffin, and M. Schambelan, “The cardiac renin-angiotensin system in STZ-induced diabetes,” Diabetes, vol. 43, no. 10, pp. 1180–1184, 1994. View at Publisher · View at Google Scholar · View at Scopus
  172. C. Tikellis, R. Pickering, D. Tsorotes et al., “Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes,” Clinical Science, vol. 123, no. 8, pp. 519–529, 2012. View at Publisher · View at Google Scholar · View at Scopus
  173. C. Xue and H. M. Siragy, “Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor,” Hypertension, vol. 46, no. 3, pp. 584–590, 2005. View at Publisher · View at Google Scholar · View at Scopus
  174. S. H. Lee, T.-H. Yoo, B.-Y. Nam et al., “Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions,” American Journal of Physiology—Renal Physiology, vol. 297, no. 5, pp. F1381–F1390, 2009. View at Publisher · View at Google Scholar · View at Scopus
  175. M. Fujisaki, T. Nagoshi, T. Nishikawa, T. Date, and M. Yoshimura, “Rapid induction of aldosterone synthesis in cultured neonatal rat cardiomyocytes under high glucose conditions,” BioMed Research International, vol. 2013, Article ID 161396, 6 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  176. D. Z. An, A. N. D. Cat, C. Soukaseum et al., “Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling,” Hypertension, vol. 52, no. 6, pp. 1060–1067, 2008. View at Publisher · View at Google Scholar · View at Scopus
  177. C. A. Lemarié, P. Paradis, and E. L. Schiffrin, “New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone,” Journal of Molecular Medicine, vol. 86, no. 6, pp. 673–678, 2008. View at Publisher · View at Google Scholar · View at Scopus
  178. S. Bernardi, B. Toffoli, C. Zennaro et al., “Aldosterone effects on glomerular structure and function,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 16, no. 4, pp. 730–738, 2015. View at Publisher · View at Google Scholar · View at Scopus
  179. M. Yamamuro, M. Yoshimura, M. Nakayama et al., “Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes,” Circulation Journal, vol. 72, no. 8, pp. 1346–1350, 2008. View at Publisher · View at Google Scholar · View at Scopus
  180. C. H. Mandavia, A. R. Aroor, V. G. Demarco, and J. R. Sowers, “Molecular and metabolic mechanisms of cardiac dysfunction in diabetes,” Life Sciences, vol. 92, no. 11, pp. 601–608, 2013. View at Publisher · View at Google Scholar · View at Scopus
  181. M. C. Thomas, C. Tikellis, W. M. Burns et al., “Interactions between renin angiotensin system and advanced glycation in the kidney,” Journal of the American Society of Nephrology, vol. 16, no. 10, pp. 2976–2984, 2005. View at Publisher · View at Google Scholar · View at Scopus
  182. G. Nickenig, O. Jung, K. Strehlow et al., “Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 272, no. 6, pp. H2701–H2707, 1997. View at Google Scholar · View at Scopus
  183. G. Nickenig, A. T. Bäumer, Y. Temur, D. Kebben, F. Jockenhövel, and M. Böhm, “Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men,” Circulation, vol. 100, no. 21, pp. 2131–2134, 1999. View at Publisher · View at Google Scholar · View at Scopus
  184. D. Gurantz, R. T. Cowling, F. J. Villarreal, and B. H. Greenberg, “Tumor necrosis factor-α upregulates angiotensin II type 1 receptors on cardiac fibroblasts,” Circulation Research, vol. 85, no. 3, pp. 272–279, 1999. View at Publisher · View at Google Scholar · View at Scopus
  185. H. Urata, B. Healy, R. W. Stewart, F. M. Bumpus, and A. Husain, “Angiotensin II-forming pathways in normal and failing human hearts,” Circulation Research, vol. 66, no. 4, pp. 883–890, 1990. View at Publisher · View at Google Scholar · View at Scopus
  186. H. Urata, A. Kinoshita, D. M. Perez et al., “Cloning of the gene and cDNA for human heart chymase,” The Journal of Biological Chemistry, vol. 266, no. 26, pp. 17173–17179, 1991. View at Google Scholar · View at Scopus
  187. K. Huynh, B. C. Bernardo, J. R. McMullen, and R. H. Ritchie, “Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways,” Pharmacology and Therapeutics, vol. 142, no. 3, pp. 375–415, 2014. View at Publisher · View at Google Scholar · View at Scopus
  188. C. Tikellis, K. Bialkowski, J. Pete et al., “ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes,” Diabetes, vol. 57, no. 4, pp. 1018–1025, 2008. View at Publisher · View at Google Scholar · View at Scopus
  189. C. Tikellis, S. Bernardi, and W. C. Burns, “Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease,” Current Opinion in Nephrology and Hypertension, vol. 20, no. 1, pp. 62–68, 2011. View at Publisher · View at Google Scholar · View at Scopus
  190. C.-C. Wei, B. Tian, G. Perry et al., “Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 282, no. 6, pp. H2254–H2258, 2002. View at Publisher · View at Google Scholar · View at Scopus
  191. C. Li, L. Cao, Q. Zeng et al., “Taurine may prevent diabetic rats from developing cardiomyopathy also by downregulating angiotensin II type2 receptor expression,” Cardiovascular Drugs and Therapy, vol. 19, no. 2, pp. 105–112, 2005. View at Publisher · View at Google Scholar · View at Scopus
  192. A. C. Hakam and T. Hussain, “Renal angiotensin II type-2 receptors are upregulated and mediate the candesartan-induced natriuresis/diuresis in obese Zucker rats,” Hypertension, vol. 45, no. 2, pp. 270–275, 2005. View at Publisher · View at Google Scholar · View at Scopus
  193. S. Mezzano, A. Droguett, M. Eugenia Burgos et al., “Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy,” Kidney International, Supplement, vol. 64, no. 86, pp. S64–S70, 2003. View at Google Scholar · View at Scopus
  194. I. Dhande, Q. Ali, and T. Hussain, “Proximal tubule angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10: role in renoprotection in obese rats,” Hypertension, vol. 61, no. 6, pp. 1218–1226, 2013. View at Publisher · View at Google Scholar · View at Scopus
  195. Q. Ali, R. Sabuhi, and T. Hussain, “High glucose up-regulates angiotensin II subtype 2 receptors via interferon regulatory factor-1 in proximal tubule epithelial cells,” Molecular and Cellular Biochemistry, vol. 344, no. 1-2, pp. 65–71, 2010. View at Publisher · View at Google Scholar · View at Scopus
  196. A. Ichihara, H. Itoh, and T. Inagami, “Critical roles of (pro)renin receptor-bound prorenin in diabetes and hypertension: sallies into therapeutic approach,” Journal of the American Society of Hypertension, vol. 2, no. 1, pp. 15–19, 2008. View at Publisher · View at Google Scholar · View at Scopus
  197. D. M. Wilson and J. A. Luetscher, “Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus,” New England Journal of Medicine, vol. 323, no. 16, pp. 1101–1106, 1990. View at Publisher · View at Google Scholar · View at Scopus
  198. J. Deinum, B. Rønn, E. Mathiesen, F. H. M. Derkx, W. C. J. Hop, and M. A. D. H. Schalekamp, “Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus,” Diabetologia, vol. 42, no. 8, pp. 1006–1010, 1999. View at Publisher · View at Google Scholar · View at Scopus
  199. K. A. Connelly, A. Advani, S. Kim et al., “The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy,” Journal of Hypertension, vol. 29, no. 6, pp. 1175–1184, 2011. View at Publisher · View at Google Scholar · View at Scopus
  200. J. J. V. McMurray, “Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances,” European Journal of Heart Failure, vol. 17, no. 3, pp. 242–247, 2015. View at Publisher · View at Google Scholar · View at Scopus
  201. M. T. Rademaker, C. J. Charles, E. A. Espiner, M. G. Nicholls, A. M. Richards, and T. Kosoglou, “Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II,” Journal of Cardiovascular Pharmacology, vol. 31, no. 1, pp. 116–125, 1998. View at Publisher · View at Google Scholar · View at Scopus
  202. N. C. Trippodo, M. Fox, T. M. Monticello, B. C. Panchal, and M. M. Asaad, “Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril,” Journal of Cardiovascular Pharmacology, vol. 34, no. 6, pp. 782–790, 1999. View at Publisher · View at Google Scholar · View at Scopus
  203. J. B. Kostis, M. Packer, H. R. Black, R. Schmieder, D. Henry, and E. Levy, “Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial,” American Journal of Hypertension, vol. 17, no. 2, pp. 103–111, 2004. View at Publisher · View at Google Scholar · View at Scopus
  204. M. Packer, R. M. Califf, M. A. Konstam et al., “Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE),” Circulation, vol. 106, no. 8, pp. 920–926, 2002. View at Publisher · View at Google Scholar · View at Scopus
  205. J. J. V. McMurray, M. Packer, A. S. Desai et al., “Angiotensin-neprilysin inhibition versus enalapril in heart failure,” The New England Journal of Medicine, vol. 371, no. 11, pp. 993–1004, 2014. View at Publisher · View at Google Scholar · View at Scopus
  206. S. L. Kristensen, D. Preiss, P. S. Jhund et al., “Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial,” Circulation: Heart Failure, vol. 9, no. 1, 2016. View at Publisher · View at Google Scholar · View at Scopus
  207. Y. Suematsu, S.-I. Miura, M. Goto et al., “LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice,” European Journal of Heart Failure, vol. 18, no. 4, pp. 386–393, 2016. View at Publisher · View at Google Scholar · View at Scopus
  208. P. Namsolleck and T. Unger, “Aldosterone synthase inhibitors in cardiovascular and renal diseases,” Nephrology Dialysis Transplantation, vol. 29, no. 1, pp. i62–i68, 2014. View at Publisher · View at Google Scholar · View at Scopus
  209. A. Fiebeler, J. Nussberger, E. Shagdarsuren et al., “Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage,” Circulation, vol. 111, no. 23, pp. 3087–3094, 2005. View at Publisher · View at Google Scholar · View at Scopus
  210. P. Mulder, V. Mellin, J. Favre et al., “Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone,” European Heart Journal, vol. 29, no. 17, pp. 2171–2179, 2008. View at Publisher · View at Google Scholar · View at Scopus
  211. A. Gamliel-Lazarovich, A. Gantman, R. Coleman, A. Y. Jeng, M. Kaplan, and S. Keidar, “FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice,” Journal of Hypertension, vol. 28, no. 9, pp. 1900–1907, 2010. View at Publisher · View at Google Scholar · View at Scopus
  212. T. Unger, L. Paulis, and D. A. Sica, “Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches,” European Heart Journal, vol. 32, no. 22, pp. 2739–2747, 2011. View at Publisher · View at Google Scholar · View at Scopus
  213. H.-H. Parving, B. M. Brenner, J. J. V. McMurray et al., “Cardiorenal end points in a trial of aliskiren for type 2 diabetes,” The New England Journal of Medicine, vol. 367, no. 23, pp. 2204–2213, 2012. View at Publisher · View at Google Scholar · View at Scopus
  214. J. H. Schefe, C. Neumann, M. Goebel et al., “Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren,” Journal of Hypertension, vol. 26, no. 9, pp. 1787–1794, 2008. View at Publisher · View at Google Scholar · View at Scopus
  215. J. E. Sealey and J. H. Laragh, “Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness,” American Journal of Hypertension, vol. 20, no. 5, pp. 587–597, 2007. View at Publisher · View at Google Scholar · View at Scopus
  216. M. P. Ocaranza, I. Godoy, J. E. Jalil et al., “Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat,” Hypertension, vol. 48, no. 4, pp. 572–578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  217. C. M. Ferrario, J. Jessup, M. C. Chappell et al., “Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2,” Circulation, vol. 111, no. 20, pp. 2605–2610, 2005. View at Publisher · View at Google Scholar · View at Scopus
  218. M. A. Crackower, R. Sarao, G. Y. Oudit et al., “Angiotensin-converting enzyme 2 is an essential regulator of heart function,” Nature, vol. 417, no. 6891, pp. 822–828, 2002. View at Publisher · View at Google Scholar · View at Scopus
  219. V. B. Patel, S. Bodiga, R. Basu et al., “Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis,” Circulation Research, vol. 110, no. 10, pp. 1322–1335, 2012. View at Publisher · View at Google Scholar · View at Scopus
  220. V. B. Patel, J. Mori, B. A. McLean et al., “ACE2 deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity,” Diabetes, vol. 65, no. 1, pp. 85–95, 2016. View at Publisher · View at Google Scholar
  221. B. Dong, Q. T. Yu, H. Y. Dai et al., “Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy,” Journal of the American College of Cardiology, vol. 59, no. 8, pp. 739–747, 2012. View at Publisher · View at Google Scholar · View at Scopus
  222. T. M. Murça, P. L. Moraes, C. A. B. Capuruço et al., “Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction,” Regulatory Peptides, vol. 177, no. 1–3, pp. 107–115, 2012. View at Publisher · View at Google Scholar · View at Scopus
  223. M. Haschke, M. Schuster, M. Poglitsch et al., “Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects,” Clinical Pharmacokinetics, vol. 52, no. 9, pp. 783–792, 2013. View at Publisher · View at Google Scholar · View at Scopus
  224. J. F. Giani, M. C. Muñoz, M. A. Mayer et al., “Angiotensin-(1–7) improves cardiac remodeling and inhibits growthpromoting pathways in the heart of fructose-fed rats,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 298, no. 3, pp. H1003–H1013, 2010. View at Publisher · View at Google Scholar · View at Scopus
  225. K. Singh, T. Singh, and P. L. Sharma, “Beneficial effects of angiotensin (1–7) in diabetic rats with cardiomyopathy,” Therapeutic Advances in Cardiovascular Disease, vol. 5, no. 3, pp. 159–167, 2011. View at Publisher · View at Google Scholar · View at Scopus
  226. P.-P. Hao, J.-M. Yang, M.-X. Zhang et al., “Angiotensin-(1–7) treatment mitigates right ventricular fibrosis as a distinctive feature of diabetic cardiomyopathy,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 308, no. 9, pp. H1007–H1019, 2015. View at Publisher · View at Google Scholar · View at Scopus
  227. A. M. Papinska, N. M. Mordwinkin, C. J. Meeks, S. S. Jadhav, and K. E. Rodgers, “Angiotensin-(1–7) administration benefits cardiac, renal and progenitor cell function in db/db mice,” British Journal of Pharmacology, vol. 172, no. 18, pp. 4443–4453, 2015. View at Publisher · View at Google Scholar · View at Scopus
  228. J. Mori, V. B. Patel, O. A. Alrob et al., “Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation,” Circulation: Heart Failure, vol. 7, no. 2, pp. 327–339, 2014. View at Publisher · View at Google Scholar · View at Scopus
  229. L. Ebermann, F. Spillmann, M. Sidiropoulos et al., “The angiotensin-(1–7) receptor agonist AVE0991 is cardioprotective in diabetic rats,” European Journal of Pharmacology, vol. 590, no. 1–3, pp. 276–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
  230. A. E. Loot, A. J. M. Roks, R. H. Henning et al., “Angiotensin-(1–7) attenuates the development of heart failure after myocardial infarction in rats,” Circulation, vol. 105, no. 13, pp. 1548–1550, 2002. View at Publisher · View at Google Scholar · View at Scopus
  231. I. F. Benter, M. H. M. Yousif, C. Cojocel, M. Al-Maghrebi, and D. I. Diz, “Angiotensin-(1–7) prevents diabetes-induced cardiovascular dysfunction,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 292, no. 1, pp. H666–H672, 2007. View at Publisher · View at Google Scholar · View at Scopus
  232. F. Bossi, S. Bernardi, D. De Nardo et al., “Angiotensin 1–7 significantly reduces diabetes-induced leukocyte recruitment both in vivo and in vitro,” Atherosclerosis, vol. 244, pp. 121–130, 2016. View at Publisher · View at Google Scholar · View at Scopus
  233. C. Koulis, B. S. M. Chow, M. Mckelvey et al., “AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy,” Hypertension, vol. 65, no. 5, pp. 1073–1081, 2015. View at Publisher · View at Google Scholar · View at Scopus
  234. G. Castoldi, C. R. T. di Gioia, C. Bombardi et al., “Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats,” American Journal of Physiology—Renal Physiology, vol. 307, no. 10, pp. F1123–F1131, 2014. View at Publisher · View at Google Scholar · View at Scopus
  235. A. K. Sampson, J. C. Irvine, W. A. Shihata et al., “Compound 21, a selective agonist of angiotensin AT2 receptors, prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo,” British Journal of Pharmacology, vol. 173, no. 4, pp. 729–740, 2016. View at Publisher · View at Google Scholar · View at Scopus
  236. B. S. Chow, C. Koulis, P. Krishnaswamy et al., “The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis,” Diabetologia, vol. 59, no. 8, pp. 1778–1790, 2016. View at Publisher · View at Google Scholar